Notably, patients with high EZH2 expression exhibited significantly poorer outcomes compared to those with low EZH2 expression across all pathological stages of NSCLC (P = 0.001), including the subset of patients with pathological stage I NSCLC (P = 0.006). Here, EZH2 is linked to non-small cell lung carcinoma.